GLAND — Gland Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Gland Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	34,629	44,007	36,246	56,647	56,165
Cost of Revenue
Gross Profit	19,247	22,514	18,913	34,334	35,261
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	22,594	30,007	28,030	46,762	47,255
Operating Profit	12,034	14,000	8,216	9,885	8,911
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,348	16,186	10,546	11,325	10,627
Provision for Income Taxes
Net Income After Taxes	9,970	12,117	7,810	7,725	6,985
Net Income Before Extraordinary Items
Net Income	9,970	12,117	7,810	7,725	6,985
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,970	12,117	7,810	7,725	6,985
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	63	73.6	50.3	46.9	42.4
Dividends per Share